Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

138
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
138
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

138
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
138
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

176
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
176
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

66
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
66
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

197
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
197

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
Same author

A consensus roadmap for post-traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials.

Epilepsia·2026
Same author

The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy.

CNS drugs·2026
Same author

The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil.

CNS drugs·2026
Same author

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add-on trials in drug-resistant focal epilepsy.

Epilepsia·2026
Same author

Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026

Related Experiment Video

Updated: May 21, 2025

EEG Mu Rhythm in Typical and Atypical Development
11:50

EEG Mu Rhythm in Typical and Atypical Development

Published on: April 9, 2014

25.5K

Cenobamate efficacy in specific populations.

Pavel Klein1

  • 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, USA.

Epilepsia
|March 19, 2025
PubMed
Summary

Many epilepsy patients are treatment-resistant. This overview examines antiseizure medications (ASMs) like cenobamate for refractory, pediatric, and older epilepsy patients, focusing on efficacy and safety.

Keywords:
antiseizure medicationscenobamateepilepsy in older patientspediatric epilepsytreatment‐resistant epilepsy

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

19.0K

Related Experiment Videos

Last Updated: May 21, 2025

EEG Mu Rhythm in Typical and Atypical Development
11:50

EEG Mu Rhythm in Typical and Atypical Development

Published on: April 9, 2014

25.5K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

19.0K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Medicine

Background:

  • Epilepsy affects millions, with approximately one-third of patients experiencing treatment resistance despite numerous antiseizure medications (ASMs).
  • Managing epilepsy in pediatric and older populations presents unique challenges due to metabolic differences, comorbidities, and polypharmacy.
  • Refractory epilepsies, including developmental epileptic encephalopathies like Lennox-Gastaut and Dravet syndromes, are associated with high mortality rates.

Purpose of the Study:

  • To review the use of ASMs in patients with refractory epilepsy.
  • To discuss ASM efficacy, safety, and tolerability in older and pediatric populations.
  • To highlight the role of newer ASMs, specifically cenobamate, in managing complex epilepsy cases.

Main Methods:

  • Literature review of ASM use in epilepsy.
  • Analysis of efficacy outcomes in treatment-resistant epilepsy.
  • Evaluation of safety and tolerability profiles in diverse patient groups.

Main Results:

  • Cenobamate demonstrates potential efficacy and a manageable safety profile in refractory epilepsy.
  • Consideration of age-specific metabolic and physiological factors is crucial for optimizing ASM therapy.
  • Treatment resistance remains a significant challenge in epilepsy management across all age groups.

Conclusions:

  • Optimizing ASM selection and management is critical for improving outcomes in refractory epilepsy.
  • Further research is needed to fully elucidate the long-term efficacy and safety of newer ASMs in pediatric and geriatric populations.
  • Personalized treatment approaches are essential for addressing the complexities of epilepsy in diverse patient demographics.